Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:BOLD NASDAQ:CRSP NASDAQ:HALO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.88+5.6%$2.24$0.98▼$4.46$614.38M0.467.08 million shs5.98 million shsBOLDBoundless Bio$1.39+0.7%$1.42$0.96▼$1.68$31M0.688,001 shs37,499 shsCRSPCRISPR Therapeutics$50.23+1.6%$52.38$39.81▼$78.48$4.77B1.741.67 million shs1.51 million shsHALOHalozyme Therapeutics$70.73+0.3%$67.43$51.06▼$82.22$8.36B0.881.70 million shs1.34 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics+5.62%-7.84%-18.26%-21.67%+29.66%BOLDBoundless Bio+0.72%-5.44%-7.33%+25.23%+31.75%CRSPCRISPR Therapeutics+1.60%-11.80%-4.92%+3.04%+20.98%HALOHalozyme Therapeutics+0.33%-1.22%-0.28%+11.11%+31.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.88+5.6%$2.24$0.98▼$4.46$614.38M0.467.08 million shs5.98 million shsBOLDBoundless Bio$1.39+0.7%$1.42$0.96▼$1.68$31M0.688,001 shs37,499 shsCRSPCRISPR Therapeutics$50.23+1.6%$52.38$39.81▼$78.48$4.77B1.741.67 million shs1.51 million shsHALOHalozyme Therapeutics$70.73+0.3%$67.43$51.06▼$82.22$8.36B0.881.70 million shs1.34 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics+5.62%-7.84%-18.26%-21.67%+29.66%BOLDBoundless Bio+0.72%-5.44%-7.33%+25.23%+31.75%CRSPCRISPR Therapeutics+1.60%-11.80%-4.92%+3.04%+20.98%HALOHalozyme Therapeutics+0.33%-1.22%-0.28%+11.11%+31.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.69Moderate Buy$8.52353.31% UpsideBOLDBoundless Bio 2.00Hold$4.00187.77% UpsideCRSPCRISPR Therapeutics 2.58Moderate Buy$67.0633.50% UpsideHALOHalozyme Therapeutics 2.54Moderate Buy$81.6015.37% UpsideCurrent Analyst Ratings BreakdownLatest HALO, ALLO, CRSP, and BOLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026CRSPCRISPR Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$80.006/11/2026CRSPCRISPR Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$60.006/3/2026HALOHalozyme Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$90.006/3/2026HALOHalozyme Therapeutics BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/27/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/13/2026CRSPCRISPR Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$50.00 ➝ $56.005/12/2026HALOHalozyme Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Buy (B-)5/12/2026HALOHalozyme Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$96.00 ➝ $93.005/11/2026CRSPCRISPR Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$76.005/6/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$80.00 ➝ $82.005/1/2026ALLOAllogene Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$20K32,444.10N/AN/A$1.30 per share1.45BOLDBoundless BioN/AN/AN/AN/A$4.41 per shareN/ACRSPCRISPR Therapeutics$3.51M1,380.25N/AN/A$20.17 per share2.49HALOHalozyme Therapeutics$1.40B6.01$4.79 per share14.78$0.42 per share168.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$190.89M-$0.77N/AN/AN/AN/A-56.45%-40.36%8/12/2026 (Estimated)BOLDBoundless Bio-$58.20M-$2.50N/AN/AN/AN/A-53.60%-34.66%N/ACRSPCRISPR Therapeutics-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%8/3/2026 (Estimated)HALOHalozyme Therapeutics$316.89M$2.7825.447.700.2923.13%187.91%21.92%8/4/2026 (Estimated)Latest HALO, ALLO, CRSP, and BOLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ALLOAllogene Therapeutics-$0.19-$0.18+$0.01-$0.18$0.00 millionN/A5/11/2026Q1 2026HALOHalozyme Therapeutics$1.54$1.60+$0.06$1.22$358.60 million$376.71 million5/8/2026Q1 2026BOLDBoundless Bio-$0.51-$0.60-$0.09-$0.60N/AN/A5/4/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million3/31/2026Q1 2026CRSPCRISPR TherapeuticsN/A-$1.28N/A-$1.28N/A$1.46 million3/12/2026Q4 2025ALLOAllogene Therapeutics-$0.25-$0.17+$0.08-$0.17$0.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/ABOLDBoundless BioN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.659.65BOLDBoundless Bio0.529.879.87CRSPCRISPR Therapeutics0.3217.9717.96HALOHalozyme Therapeutics8.812.762.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%BOLDBoundless BioN/ACRSPCRISPR Therapeutics69.20%HALOHalozyme Therapeutics97.79%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%BOLDBoundless Bio23.10%CRSPCRISPR Therapeutics4.30%HALOHalozyme Therapeutics2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310345.15 million299.60 millionOptionableBOLDBoundless Bio6422.46 million17.28 millionNo DataCRSPCRISPR Therapeutics46096.45 million92.30 millionOptionableHALOHalozyme Therapeutics390118.61 million115.65 millionOptionableHALO, ALLO, CRSP, and BOLD HeadlinesRecent News About These CompaniesHalozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?June 10 at 12:31 PM | zacks.comNatixis Advisors LLC Has $6.68 Million Holdings in Halozyme Therapeutics, Inc. $HALOJune 8, 2026 | marketbeat.comSky Harbour: The Ultimate HALO Investment Taking FlightJune 7, 2026 | seekingalpha.comLos Angeles Capital Management LLC Has $70.83 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALOJune 7, 2026 | marketbeat.comPrudential PLC Buys 31,077 Shares of Halozyme Therapeutics, Inc. $HALOJune 7, 2026 | marketbeat.comBI Asset Management Fondsmaeglerselskab A S Trims Position in Halozyme Therapeutics, Inc. $HALOJune 7, 2026 | marketbeat.comHow New ENHANZE Data And Analyst Support At Halozyme Therapeutics (HALO) Has Changed Its Investment StoryJune 6, 2026 | finance.yahoo.comTD Asset Management Inc Lowers Position in Halozyme Therapeutics, Inc. $HALOJune 6, 2026 | marketbeat.comWhy is Halozyme Therapeutics (HALO) stock rocketing higher today?June 5, 2026 | msn.comNorges Bank Buys New Stake in Halozyme Therapeutics, Inc. $HALOJune 5, 2026 | marketbeat.comWhat is Zacks Research's Estimate for HALO Q2 Earnings?June 4, 2026 | marketbeat.comBNP Paribas Financial Markets Trims Stock Holdings in Halozyme Therapeutics, Inc. $HALOJune 4, 2026 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) CEO Sells $690,700.00 in StockJune 3, 2026 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,351,600.00 in StockJune 3, 2026 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Trading Up 5.6% - Here's What HappenedJune 3, 2026 | marketbeat.comZacks Research Has Positive Forecast for HALO Q3 EarningsJune 3, 2026 | marketbeat.comLegal & General Group Plc Cuts Holdings in Halozyme Therapeutics, Inc. $HALOJune 1, 2026 | marketbeat.comAnti-AI Investing: The HALO MoatMay 31, 2026 | seekingalpha.comHalozyme Therapeutics, Inc. $HALO Stake Boosted by Intech Investment Management LLCMay 30, 2026 | marketbeat.comFuture Fund LLC Increases Stock Holdings in Halozyme Therapeutics, Inc. $HALOMay 30, 2026 | marketbeat.comSouth Street Advisors LLC Has $15.60 Million Stake in Halozyme Therapeutics, Inc. $HALOMay 29, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 20263 Stocks to Own If Gas Prices Keep RisingBy Dan Schmidt | May 16, 2026HALO, ALLO, CRSP, and BOLD Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.88 +0.10 (+5.62%) Closing price 06/11/2026 04:00 PM EasternExtended Trading$1.90 +0.02 (+1.06%) As of 07:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Boundless Bio NASDAQ:BOLD$1.39 +0.01 (+0.72%) Closing price 06/11/2026 04:00 PM EasternExtended Trading$1.44 +0.06 (+3.96%) As of 06/11/2026 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.CRISPR Therapeutics NASDAQ:CRSP$50.23 +0.79 (+1.60%) Closing price 06/11/2026 04:00 PM EasternExtended Trading$50.72 +0.50 (+0.99%) As of 07:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Halozyme Therapeutics NASDAQ:HALO$70.73 +0.23 (+0.33%) Closing price 06/11/2026 04:00 PM EasternExtended Trading$70.75 +0.02 (+0.03%) As of 07:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Microsoft Just Gave Investors 3 Dates They Can't Afford to Ignore SpaceX IPO Fears Are Overblown, But the AI Bet Is Real The Biggest Opportunity From SpaceX’s IPO May Surprise You NVIDIA’s Outlook Gains Momentum: Stock Price to Follow Chewy’s Growth Engine Is Stronger Than the Market Thinks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
